Considering the claims, page-76

For what it's worth... I think the time for Mylan's bravado is over. POH are not going to run out of money before the decision is made. The regulators seem to have little or no simpath for Mylan. A decision could come without warning / consultation and their only bargaining chip being the tpm daptomyocin license may be taken away without further consideration too. And that's where the real value may be for POH, a virtually market daptomyocin product with POH TPM (?$50mil per year) I expect negotiations are taking place as we speak....